November 22, 2014 4:24 PM ET

Pharmaceuticals

Company Overview of Millennium Pharmaceuticals, Inc.

Company Overview

Millennium Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of medicines for the treatment of cancer in the United States and internationally. The company develops and markets VELCADE for injection, a cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. It also focuses on developing ADCETRIS (brentuximab vedotin), an antibody-drug conjugate that is used for the treatment of Hodgkin lymphoma patients. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts with operations in San Diego, San Francisco, Tsukuba, and Osaka. As of May 13, 2008, Millennium Pharmac...

40 Landsdowne Street

Cambridge, MA 02139

United States

Founded in 1993

966 Employees

Phone:

617-679-7000

Fax:

617-374-7788

Key Executives for Millennium Pharmaceuticals, Inc.

President of Global Oncology Business Unit
Age: 52
Senior Vice President of Non-Clinical Development Sciences
Age: 59
Chief Medical Officer
Age: 56
Head of Drug Discovery Unit
Head of Oncology Therapeutic Area Unit
Compensation as of Fiscal Year 2014.

Millennium Pharmaceuticals, Inc. Key Developments

Millennium, Subsystem Technologies Inc, WisEngineering LLC and International Logistics Systems, Inc. Win $29,967,029 Federal Contract

Millennium was awarded a share of a $29,967,029 federal contract by the U.S. Army Contracting Command, Picatinny Arsenal, New Jersey, for weapon system and munitions life cycle supportability services in support of the Army Research Development and Engineering Command. Subsystem Technologies Inc.; WisEngineering LLC; and International Logistics Systems, Inc. shared in the award amount.

Harris & Harris Group, Inc. Enters into Collaboration Agreement with Millennium Pharmaceuticals, Inc. to Develop Next-Generation Fleximer(R) Antibody-Drug Conjugates

Harris & Harris Group, Inc. announced that it has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc. to develop next-generation Fleximer(R) antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology is comprised of the company's biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to Mersana's diverse, cytotoxic payloads. Under the agreement, Takeda will provide an upfront payment to Mersana for the right to utilize Fleximer technology to develop novel ADC candidates. Mersana is responsible for conducting research and creating ADCs that are conjugates of Takeda's antibodies and Mersana's diverse payload platforms, which combine a cytotoxic payload with the Fleximer polymer and custom linkers. In addition to providing antibodies, Takeda is responsible for product development, manufacturing and commercialization of any Fleximer-ADC products. Mersana, in addition to an upfront payment, is eligible to receive milestones and royalties on worldwide net sales of any resulting ADC products.

Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates

Mersana Therapeutics, Inc. announced that it has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc. to develop next-generation, Fleximer(R) antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology is comprised of the company's biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to Mersana's diverse, cytotoxic payloads. Under the agreement, Takeda will provide an upfront payment to Mersana for the right to utilize Fleximer technology to develop novel ADC candidates. Mersana is responsible for conducting research and creating ADCs that are conjugates of Takeda's antibodies and Mersana's diverse payload platforms, which combine a cytotoxic payload with the Fleximer polymer and custom linkers. In addition to providing antibodies, Takeda is responsible for product development, manufacturing and commercialization of any Fleximer-ADC products. In addition to an upfront payment, Mersana is eligible to receive milestones and royalties on worldwide net sales of any resulting ADC products.

Similar Private Companies By Industry

Company Name Region
Organon API Inc. United States
pHase Pharmaceuticals, LLC United States
Rempex Pharmaceuticals, Inc. United States
SOV Therapeutics, Inc. United States
PeriCor Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Millennium Pharmaceuticals, Inc., please visit www.millennium.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.